BioCryst Pharmaceuticals BCRX Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — total revenues?
- BioCryst Pharmaceuticals (BCRX) reported business segments — total revenues of $156.41M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — total revenues changed year-over-year?
- BioCryst Pharmaceuticals's business segments — total revenues increased by 7.5% year-over-year, from $145.53M to $156.41M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — total revenues?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — total revenues has grown at a 47.8% compound annual growth rate (CAGR), from $270.83M to $874.84M.
- What does business segments — total revenues mean?
- Represents the total gross income generated by the business segment from its primary operations, including product sales and licensing. This metric serves as a key indicator of the segment's market demand and commercial success in its specific therapeutic areas.